Details of the Drug

General Information of Drug (ID: DM3NUMH)

Drug Name

Aripiprazole

Synonyms

129722-12-9; Abilify; Abilitat; Abilify Discmelt; OPC-14597; Discmelt; Opc 14597; OPC 31; OPC-31; 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril; UNII-82VFR53I78; C23H27Cl2N3O2; HSDB 7320; 7-(4-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)BUTOXY)-3,4-DIHYDROQUINOLIN-2(1H)-ONE; CHEMBL1112; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone; CHEBI:31236; Abilify; Aripiprazol; Aripiprazolum; Aripirazole; Arpizol; Asprito; Pripiprazole; Aripiprazole [USAN]; Otsuka brand of aripiprazole; OPC 14597; ALKS-9070; Abilify (TN); BMS-337039; Bristol-Myers Squibb brand of aripiprazole; Discmelt (TN); KS-1030; S06-0010; Aripiprazole (JAN/USAN/INN); 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril; 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one; ALKS9070/ALKS9072; Aripiprazole/escitalopram fixed-dose combination

Indication

Disease Entry	ICD 11	Status	REF
Erythropoietic porphyrias	5C58.12	Approved	[1]
Schizophrenia	6A20	Approved	[2], [3]
Major depressive disorder	6A70.3	Phase 3	[4]
Bipolar disorder	6A60	Application submitted	[5]

Therapeutic Class

Antipsychotic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

448.4

Topological Polar Surface Area (xlogp)

4.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [6]
Bioavailability: 87% of drug becomes completely available to its intended biological destination(s) [7]
Clearance: The clearance of drug is 0.8 mL/min/kg [8]
Elimination: 25% of a given dose will be eliminated in urine and 55% in the feces [9]
Half-life: The concentration or amount of drug in body reduced by one-half in 75 hours [10]
Metabolism: The drug is metabolized via the hepatic [8]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.55754 micromolar/kg/day [11]
Unbound Fraction: The unbound fraction of drug in plasma is 0.01% [12]
Vd: The volume of distribution (Vd) of drug is 404 L or 4.9 L/kg [13]
Water Solubility: The ability of drug to dissolve in water is measured as 0.0001 mg/mL [6]

Chemical Identifiers

Formula: C23H27Cl2N3O2
IUPAC Name: 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
Canonical SMILES: C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl
InChI: InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
InChIKey: CEUORZQYGODEFX-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 60795
ChEBI ID: CHEBI:31236
CAS Number: 129722-12-9
DrugBank ID: DB01238
TTD ID: D0H3HM
VARIDT ID: DR00766
INTEDE ID: DR0136
ACDINA ID: D00043

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Agonist	[14]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[15]
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[15]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[16]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[16]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Erythropoietic porphyrias

ICD Disease Classification

5C58.12

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.20E-03	-0.51	-1.35
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.57E-01	9.43E-03	1.29E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.70E-01	2.98E-02	1.22E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.76E-01	1.26E-01	8.27E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Aripiprazole

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Iloperidone.	Schizophrenia [6A20]	[56]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Paliperidone.	Schizophrenia [6A20]	[56]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Molindone.	Schizophrenia [6A20]	[56]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Thiothixene.	Schizophrenia [6A20]	[56]
Amisulpride	DMSJVAM	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Amisulpride.	Schizophrenia [6A20]	[57]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Asenapine.	Schizophrenia [6A20]	[56]
-----------


⏷ Show the Full List of 6 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Aripiprazole (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Aripiprazole caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[58]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Midostaurin.	Acute myeloid leukaemia [2A60]	[57]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Aripiprazole caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[58]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Gilteritinib.	Acute myeloid leukaemia [2A60]	[57]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Oliceridine.	Acute pain [MG31]	[57]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[59]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[59]
Bepridil	DM0RKS4	Moderate	Additive hypotensive effects by the combination of Aripiprazole and Bepridil.	Angina pectoris [BA40]	[60]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Aripiprazole caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[58]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Aripiprazole and Amyl nitrite.	Angina pectoris [BA40]	[60]
Bedaquiline	DM3906J	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[57]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Aripiprazole caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[58]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Levalbuterol.	Asthma [CA23]	[57]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Pirbuterol.	Asthma [CA23]	[57]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[57]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Aripiprazole caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[61]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Aripiprazole caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[58]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Cariprazine.	Bipolar disorder [6A60]	[56]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Aripiprazole caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[58]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Eribulin.	Breast cancer [2C60-2C6Y]	[57]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Aripiprazole caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[57]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Aripiprazole caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[58]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Bosutinib.	Breast cancer [2C60-2C6Y]	[57]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Aripiprazole when combined with Acetylcholine.	Cataract [9B10]	[62]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[57]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[63]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[57]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[57]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[63]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[63]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[57]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[57]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Aripiprazole and Dihydrocodeine.	Chronic pain [MG30]	[64]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Probucol.	Coronary atherosclerosis [BA80]	[57]
Pasireotide	DMHM7JS	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Pasireotide.	Cushing syndrome [5A70]	[57]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Osilodrostat.	Cushing syndrome [5A70]	[57]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Aripiprazole caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[58]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Aripiprazole caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[58]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Aripiprazole caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[58]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Aripiprazole and Cyclandelate.	Dementia [6D80-6D8Z]	[60]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and OPC-34712.	Depression [6A70-6A7Z]	[56]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Clomipramine.	Depression [6A70-6A7Z]	[56]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Aripiprazole and Esketamine.	Depression [6A70-6A7Z]	[57]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Mepenzolate.	Digestive system disease [DE2Z]	[56]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Aripiprazole and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[65]
Deutetrabenazine	DMUPFLI	Major	Additive antidopaminergic effects by the combination of Aripiprazole and Deutetrabenazine.	Dystonic disorder [8A02]	[66]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Aripiprazole caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[58]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Aripiprazole caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[58]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Aripiprazole caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[58]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Aripiprazole caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[58]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Aripiprazole caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[58]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Solifenacin.	Functional bladder disorder [GC50]	[56]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Aripiprazole caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[58]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[57]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Aripiprazole caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[58]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Aripiprazole caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[58]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Aripiprazole caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[58]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Aripiprazole caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[58]
BMS-201038	DMQTAGO	Moderate	Decreased metabolism of Aripiprazole caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[58]
Penbutolol	DM4ES8F	Moderate	Additive hypotensive effects by the combination of Aripiprazole and Penbutolol.	Hypertension [BA00-BA04]	[60]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Aripiprazole and Nebivolol.	Hypertension [BA00-BA04]	[60]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Aripiprazole and Levamlodipine.	Hypertension [BA00-BA04]	[60]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Aripiprazole and TAK-491.	Hypertension [BA00-BA04]	[60]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Aripiprazole and Hydralazine.	Hypertension [BA00-BA04]	[60]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Aripiprazole and Clevidipine butyrate.	Hypertension [BA00-BA04]	[60]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Aripiprazole caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[58]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Aripiprazole caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[58]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[56]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Aripiprazole caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[58]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and ITI-007.	Insomnia [7A00-7A0Z]	[56]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Aripiprazole and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[67]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Aripiprazole caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[58]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Aripiprazole caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[58]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Aripiprazole caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[58]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Aripiprazole caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[58]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Aripiprazole caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[58]
Osimertinib	DMRJLAT	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Osimertinib.	Lung cancer [2C25]	[57]
Selpercatinib	DMZR15V	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Selpercatinib.	Lung cancer [2C25]	[57]
Lumefantrine	DM29GAD	Moderate	Decreased metabolism of Aripiprazole caused by Lumefantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[61]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Hydroxychloroquine.	Malaria [1F40-1F45]	[57]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[57]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Aripiprazole caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[58]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Aripiprazole caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[58]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Aripiprazole caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[57]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and LGX818.	Melanoma [2C30]	[57]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Aripiprazole caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[58]
Danazol	DML8KTN	Moderate	Decreased metabolism of Aripiprazole caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[58]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Aripiprazole and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[68]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Aripiprazole and Lasmiditan.	Migraine [8A80]	[69]
Exjade	DMHPRWG	Moderate	Increased metabolism of Aripiprazole caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[58]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Aripiprazole and Flibanserin.	Mood disorder [6A60-6E23]	[70]
Panobinostat	DM58WKG	Moderate	Decreased metabolism of Aripiprazole caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[58]
Siponimod	DM2R86O	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Siponimod.	Multiple sclerosis [8A40]	[57]
Fingolimod	DM5JVAN	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Fingolimod.	Multiple sclerosis [8A40]	[57]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Aripiprazole and Ozanimod.	Multiple sclerosis [8A40]	[71]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Romidepsin.	Mycosis fungoides [2B01]	[57]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Aripiprazole caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[58]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Aripiprazole caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[57]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Phenindamine.	Nasopharyngitis [CA00]	[56]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Aripiprazole caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[72]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Aripiprazole caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[61]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Entrectinib.	Non-small cell lung cancer [2C25]	[57]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Aripiprazole caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[73]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Aripiprazole and Polythiazide.	Oedema [MG29]	[60]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Aripiprazole and Lofexidine.	Opioid use disorder [6C43]	[60]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Aripiprazole caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[57]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Triclabendazole.	Parasitic worm infestation [1F90]	[57]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Aripiprazole when combined with Opicapone.	Parkinsonism [8A00]	[74]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Pimavanserin.	Parkinsonism [8A00]	[57]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Aripiprazole caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[75]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Methylscopolamine.	Peptic ulcer [DA61]	[56]
Macimorelin	DMQYJIR	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[57]
Lefamulin	DME6G97	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Lefamulin.	Pneumonia [CA40]	[57]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Aripiprazole caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[58]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Degarelix.	Prostate cancer [2C82]	[57]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Aripiprazole caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[57]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Aripiprazole and Silodosin.	Prostate hyperplasia [GA90]	[60]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Levomepromazine.	Psychotic disorder [6A20-6A25]	[56]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Aripiprazole and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[76]
Neupro	DMHEAB1	Moderate	Additive hypotensive effects by the combination of Aripiprazole and Neupro.	Restless legs syndrome [7A80]	[74]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Aripiprazole caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[58]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Aripiprazole caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[77]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Aripiprazole caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[58]
Armodafinil	DMGB035	Minor	Increased metabolism of Aripiprazole caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[78]
LEE011	DMMX75K	Moderate	Decreased metabolism of Aripiprazole caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[58]
Vandetanib	DMRICNP	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[57]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[57]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Pitolisant.	Somnolence [MG42]	[77]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[57]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Aripiprazole caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[79]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Aripiprazole caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[58]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Lenvatinib.	Thyroid cancer [2D10]	[57]
Cabozantinib	DMIYDT4	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Cabozantinib.	Thyroid cancer [2D10]	[57]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Aripiprazole caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[58]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Aripiprazole and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[57]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Aripiprazole and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[56]
-----------


⏷ Show the Full List of 138 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Acesulfame	E00341	36573	Flavoring agent
Allura red AC dye	E00338	33258	Colorant
Aspartame	E00402	134601	Flavoring agent
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Calcium silicate	E00533	21910000	Adsorbent; Anticaking agent; Diluent; Opacifying agent
Calcium stearate	E00244	15324	lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Disodium hydrogenorthophosphate	E00283	24203	Buffering agent; Complexing agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polysorbate 20	E00664	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium citrate dihydrate	E00369	71474	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium dihydrogenorthophosphate	E00559	23672064	Buffering agent; Complexing agent
Sorbitan monolaurate	E00508	11046239	Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Tartaric acid	E00029	875	Acidulant; Complexing agent; Flavoring agent
Water	E00035	962	Solvent
Xylitol	E00136	6912	Coating agent; Diluent; Emollient; Flavoring agent; Humectant
--------------------


⏷ Show the Full List of 24 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Aripiprazole 10 mg tablet	10 mg	Disintegrating Oral Tablet	Oral
Aripiprazole 15 mg tablet	15 mg	Disintegrating Oral Tablet	Oral
Aripiprazole 2 mg tablet	2 mg	Oral Tablet	Oral
Aripiprazole 5 mg tablet	5 mg	Oral Tablet	Oral
Aripiprazole Lauroxil 662mg/2.4ml extended release suspension	662mg/2.4ml	Extended Release Suspension	Intramuscular
Aripiprazole Lauroxil 1064mg/3.9ml extended release suspension	1064mg/3.9ml	Extended Release Suspension	Intramuscular
Aripiprazole Lauroxil 441mg/1.6ml extended release suspension	441mg/1.6ml	Extended Release Suspension	Intramuscular
Aripiprazole Lauroxil 882mg/3.2ml extended release suspension	882mg/3.2ml	Extended Release Suspension	Intramuscular
Aripiprazole 10 mg tablet	10 mg	Oral Tablet	Oral
Aripiprazole 15 mg tablet	15 mg	Oral Tablet	Oral
Aripiprazole 30 mg tablet	30 mg	Oral Tablet	Oral
Aripiprazole 20 mg tablet	20 mg	Oral Tablet	Oral
Aripiprazole Lauroxil 675mg/2.4ml extended release suspension	675mg/2.4ml	Extended Release Suspension	Intramuscular

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 34).
3	Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. Psychopharmacology (Berl). 2009 Oct;206(2):335-44.
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034267)
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	BDDCS applied to over 900 drugs
7	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
8	Liao S, Liang Y, Zhang Z, Li J, Wang J, Wang X, Dou G, Zhang Z, Liu K: In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products. PLoS One. 2015 Feb 27;10(2):e0116805. doi: 10.1371/journal.pone.0116805. eCollection 2015.
9	Prommer E: Aripiprazole. Am J Hosp Palliat Care. 2017 Mar;34(2):180-185. doi: 10.1177/1049909115612800. Epub 2016 Jul 10.
10	Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet. 2007 Oct;22(5):358-66.
11	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
12	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
13	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
14	Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5.
15	Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.
16	Drug Interactions Flockhart Table
17	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
18	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
19	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
20	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
21	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
22	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
23	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
24	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
25	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
26	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
27	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
28	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
29	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
30	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
31	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
32	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
33	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
34	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
35	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
36	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
37	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
38	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
39	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
40	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
41	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
42	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
43	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
44	Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
45	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
46	The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
47	Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
48	CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
49	Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
50	Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
51	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
52	Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
53	[The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
54	Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
55	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
56	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
57	Cerner Multum, Inc. "Australian Product Information.".
58	Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
59	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
60	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
61	Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
62	Multum Information Services, Inc. Expert Review Panel.
63	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
64	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
65	Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
66	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
67	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
68	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
69	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
70	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
71	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
72	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
73	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
74	Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
75	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
76	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
77	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
78	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
79	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.